{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T10:56:28Z","timestamp":1788260188085,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T00:00:00Z","timestamp":1686528000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.jtct.2023.05.022","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T22:36:52Z","timestamp":1686263812000},"page":"575.e1-575.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Triple-Drug Graft-versus-Host Disease Prophylaxis after HLA-Matched Unrelated Donor Nonmyeloablative Allogenic Hematopoietic Stem Cell Transplantation"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6020-0659","authenticated-orcid":false,"given":"Alma","family":"Wegener","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels Smedegaard","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lone Smidstrup","family":"Friis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren Lykke","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Schj\u00f8dt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Kornblit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Sengel\u00f8v","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5496-9955","authenticated-orcid":false,"given":"Lars Klingen","family":"Gj\u00e6rde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2023.05.022_bib0001","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood.V97.11.3390","article-title":"Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects","volume":"97","author":"McSweeney","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.05.022_bib0002","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1200\/JCO.2012.45.0247","article-title":"Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation","volume":"31","author":"Storb","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.05.022_bib0003","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMra052638","article-title":"Hematopoietic stem-cell transplantation","volume":"354","author":"Copelan","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.05.022_bib0004","doi-asserted-by":"crossref","first-page":"e409","DOI":"10.1016\/S2352-3026(19)30088-2","article-title":"Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial","volume":"6","author":"Sandmaier","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2023.05.022_bib0005","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","article-title":"Interpretation and impact of real-world clinical data for the practicing clinician","volume":"35","author":"Blonde","year":"2018","journal-title":"Adv Ther"},{"key":"10.1016\/j.jtct.2023.05.022_bib0006","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.05.022_bib0007","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.05.022_bib0008","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3324\/haematol.10699","article-title":"Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group","volume":"92","author":"Ruutu","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2023.05.022_bib0009","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2023.05.022_bib0010","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2991\/chi.d.191207.001","article-title":"Summary of scientific and statistical methods, study endpoints and definitions for observational and registry-based studies in hematopoietic cell transplantation","volume":"2","author":"Kanate","year":"2019","journal-title":"Clin Hematol Int"},{"key":"10.1016\/j.jtct.2023.05.022_bib0011","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2011-06-364265","article-title":"Risk factors for acute GVHD and survival after hematopoietic cell transplantation","volume":"119","author":"Jagasia","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.05.022_bib0012","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1182\/blood-2010-08-302109","article-title":"Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria","volume":"117","author":"Flowers","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.05.022_bib0013","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.bbmt.2007.04.010","article-title":"HLA association with hematopoietic stem cell transplantation outcome: the number of mismatches at HLA-A, -B, -C, -DRB1, or -DQB1 is strongly associated with overall survival","volume":"13","author":"Loiseau","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.05.022_bib0014","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1056\/NEJMra1703472","article-title":"Pathophysiology of chronic graft-versus-host disease and therapeutic targets","volume":"377","author":"Zeiser","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.05.022_bib0015","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41409-019-0624-z","article-title":"Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors","volume":"55","author":"Styczy\u0144ski","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.05.022_bib0016","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1002\/cncr.23375","article-title":"Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation","volume":"112","author":"Sorror","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2023.05.022_bib0017","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1182\/blood-2012-03-418202","article-title":"A disease risk index for patients undergoing allogeneic stem cell transplantation","volume":"120","author":"Armand","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.05.022_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100792","article-title":"Graft-versus-host disease prophylaxis: pathophysiology-based review on current approaches and future directions","volume":"48","author":"Martinez-Cibrian","year":"2021","journal-title":"Blood Rev"},{"key":"10.1016\/j.jtct.2023.05.022_bib0019","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2007-06-094482","article-title":"Differential impact of mammalian target of rapamycin inhibition on CD4 +CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells","volume":"111","author":"Zeiser","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.05.022_bib0020","doi-asserted-by":"crossref","unstructured":"Monti P, Mercalli A, Leone BE, Valerio DC, Allavena P, Piemonti L. Rapamycin impairs antigen uptake of human dendritic cells. Transplantation. 2003;75:137-145. https:\/\/doi.org\/10.1097\/00007890-200301150-00025","DOI":"10.1097\/00007890-200301150-00025"},{"key":"10.1016\/j.jtct.2023.05.022_bib0021","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.1182\/blood-2002-11-3370","article-title":"Rapamycin inhibits IL-4-induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo","volume":"101","author":"Hackstein","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.05.022_bib0022","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1182\/blood-2007-01-069294","article-title":"Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis","volume":"110","author":"Marty","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.05.022_bib0023","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.bbmt.2010.03.020","article-title":"Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease","volume":"16","author":"Cantoni","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.05.022_bib0024","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.beha.2008.02.005","article-title":"GVHD pathophysiology: is acute different from chronic?","volume":"21","author":"Toubai","year":"2008","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.jtct.2023.05.022_bib0025","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/bmt.2013.129","article-title":"Uptake and use of recommendations for the diagnosis, severity scoring and management of chronic GVHD: an international survey of the EBMT-NCI Chronic GVHD Task Force","volume":"49","author":"Duarte","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.05.022_bib0026","article-title":"The addition of sirolimus to GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation: a meta-analysis of efficacy and safety","volume":"11","author":"Chen","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtct.2023.05.022_bib0027","article-title":"Current use and outcome of hematopoietic stem cell transplantation:","author":"Auletta","year":"2021","journal-title":"CIBMTR US summary slides"},{"key":"10.1016\/j.jtct.2023.05.022_bib0028","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1182\/blood.V84.4.1328.1328","article-title":"Increased risk of infection in marrow transplant patients receiving methylprednisolone for graft-versus-host disease prevention","volume":"84","author":"Sayer","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.05.022_bib0029","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/cid\/ciz490","article-title":"A mortality analysis of letermovir prophylaxis for cytomegalovirus (CMV) in CMV-seropositive recipients of allogeneic hematopoietic cell transplantation","volume":"70","author":"Ljungman","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2023.05.022_bib0030","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.05.022_bib0031","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.clnu.2018.03.008","article-title":"Impact of route and adequacy of nutritional intake on outcomes of allogeneic haematopoietic cell transplantation for haematologic malignancies","volume":"38","author":"Beckerson","year":"2019","journal-title":"Clin Nutr"},{"key":"10.1016\/j.jtct.2023.05.022_bib0032","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMra1609337","article-title":"Acute graft-versus-host disease \u2014 biologic process, prevention, and therapy","volume":"377","author":"Zeiser","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.05.022_bib0033","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1182\/blood-2014-01-550566","article-title":"Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality","volume":"124","author":"Sorror","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.05.022_bib0034","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/s41409-018-0204-7","article-title":"EBMT\u2212NIH\u2212CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment","volume":"53","author":"Schoemans","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.05.022_bib0035","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/S2352-3026(19)30256-X","article-title":"Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation","volume":"7","author":"Penack","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2023.05.022_bib0036","series-title":"The EBMT Handbook","article-title":"The EBMT: history, present, and future","author":"Gratwohl","year":"2019"},{"key":"10.1016\/j.jtct.2023.05.022_bib0037","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1038\/bmt.2010.5","article-title":"Impact of GvHD on quality of life in long-term survivors of haematopoietic transplantation","volume":"45","author":"Pallua","year":"2010","journal-title":"Bone Marrow Transplant"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636723013222?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636723013222?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:10:13Z","timestamp":1763003413000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636723013222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S2666636723013222"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2023.05.022","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Triple-Drug Graft-versus-Host Disease Prophylaxis after HLA-Matched Unrelated Donor Nonmyeloablative Allogenic Hematopoietic Stem Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2023.05.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}